Compound · hexarelin
T2Peptide

Hexarelin

Synthetic hexapeptide growth hormone secretagogue with high potency at GHS-R1a. Produces strong GH pulse comparable to GHRP-2 but desensitizes the receptor within 4-8 weeks of continuous use. Notable cardiac protective effects independent of GH — direct binding to cardiac CD36 receptors.

Half-life
70 minutes
Bioavailability
Systemic via subcutaneous injection
Route
subcutaneous
Evidence tier
T2 — Single-RCT or mechanistic
Optimization pillars
recovery · muscle
References
2 peer-reviewed
Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative
100 mcg/injection 1-2x/day
GH pulse or cardiac support
moderate
100–200 mcg/injection 2x/day
Short-term GH protocol
aggressive
200–300 mcg/injection 2-3x/day
Pulse protocol with cycling
Monitoring
  • igf-1
  • fasting-glucose
  • cortisol
  • prolactin
Contraindications
  • active-cancer
  • pituitary-tumor
References
  • PMID:10721907Hexarelin, a synthetic growth hormone secretagogue: cardioprotective effects — Pharmacol Res, 2000
  • PMID:10372583Desensitization and recovery of growth hormone response to hexarelin — Growth Horm IGF Res, 1999
Notes

Hexarelin has the most interesting secondary pharmacology of any GH secretagogue. The cardiac CD36 binding is completely independent of growth hormone — it protects cardiomyocytes directly. But the receptor desensitization is the dealbreaker for long-term use. After 4-8 weeks, the GH response fades. You must cycle off. This makes hexarelin a burst tool, not a foundation compound. The cardiac data is why some researchers keep studying it despite the desensitization ceiling.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See Hexarelin in a protocol matched to you

OPTIMIZE · a protocols.is product